Want to see IN:SAKAR full AI Analyst Report?
SAKAR Stock Chart & Stats
₹802.20
₹27.80(3.47%)
At close: 4:00 PM EDT
₹802.20
₹27.80(3.47%)
Day’s Range― - ―
52-Week Range₹311.00 - ₹960.00
Previous CloseN/A
Volume110.03K
Average Volume (3M)19.08K
Market Cap
₹19.43B
Enterprise Value₹8.69K
Total Cash (Recent Filing)₹2.60M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)54.5
Beta0.66
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.23
Shares Outstanding21,949,910
10 Day Avg. Volume18,950
30 Day Avg. Volume19,083
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)3.42
Price to Sales (P/S)4.41
P/FCF Ratio100.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSakar has materially accelerated top-line growth, with FY2026 revenue up 23.4%. Durable revenue expansion indicates improving product uptake and distribution scale across domestic and export markets, which supports longer-term investment in manufacturing and R&D capacity.
ProfitabilitySolid FY2026 gross and net margins reflect profitable operating economics for finished-dosage products. Sustained mid‑teens to double‑digit margins give the company margin headroom to fund growth, absorb cost pressure, and maintain competitive pricing over the coming 2–6 months.
Balance Sheet / LeverageLeverage has been meaningfully reduced, lowering financial risk and increasing flexibility for capex, working capital, or acquisitions. A conservative D/E improves resilience to industry cyclicality and supports continuity of supply and regulatory compliance investments.
Bears Say
Weak Cash ConversionFree cash flow recovery is positive but weak relative to earnings, with FCF only ~28% of net income. Limited cash conversion constrains self-funded growth, increases reliance on external financing for expansion, and makes the company more sensitive to working capital swings.
Margin VolatilityLarge swing in gross margins suggests persistent mix shifts, pricing pressure, or rising input costs. Such volatility undermines earnings predictability and planning, and could compress long-term profitability if higher-margin products do not re-emerge or costs remain elevated.
Moderate ROEROE is improving but still modest versus peers, indicating limited capital efficiency. Sustained moderate returns reduce excess cash generation for shareholders and may require continued operational improvements or strategic moves to materially boost long‑term shareholder value.
Sakar Healthcare Ltd News
SAKAR FAQ
What was Sakar Healthcare Ltd’s price range in the past 12 months?
Sakar Healthcare Ltd lowest stock price was ₹311.00 and its highest was ₹960.00 in the past 12 months.
What is Sakar Healthcare Ltd’s market cap?
Sakar Healthcare Ltd’s market cap is ₹19.43B.
When is Sakar Healthcare Ltd’s upcoming earnings report date?
Sakar Healthcare Ltd’s upcoming earnings report date is Oct 22, 2026 which is in 77 days.
How were Sakar Healthcare Ltd’s earnings last quarter?
Sakar Healthcare Ltd released its earnings results on Jul 24, 2026. The company reported ₹4.622 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.622.
Is Sakar Healthcare Ltd overvalued?
According to Wall Street analysts Sakar Healthcare Ltd’s price is currently Overvalued.
Does Sakar Healthcare Ltd pay dividends?
Sakar Healthcare Ltd does not currently pay dividends.
What is Sakar Healthcare Ltd’s EPS estimate?
Sakar Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sakar Healthcare Ltd have?
Sakar Healthcare Ltd has 21,949,910 shares outstanding.
What happened to Sakar Healthcare Ltd’s price movement after its last earnings report?
Sakar Healthcare Ltd reported an EPS of ₹4.622 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.069%.
Which hedge fund is a major shareholder of Sakar Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:SAKAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sakar Healthcare Ltd
Sakar Healthcare Limited, founded in 2004 and based in Ahmedabad, India, is a pharmaceutical company actively involved in the full spectrum of drug development, from research and manufacturing to marketing its products. The company's diverse product line includes liquid oral medications, cephalosporin-based drugs (available as tablets, capsules, and dry powder syrups), various injectable forms such as dry powder injections, and liquid injectable solutions (supplied in ampoules, vials, and lyophilized preparations), alongside oral solid dosages. Their comprehensive portfolio addresses approximately 22 distinct therapeutic categories, encompassing treatments for conditions like acidity, malaria, blood clotting, constipation, respiratory issues, pain, infections, depression, allergies, and nutritional deficiencies, among others. Sakar Healthcare also has a significant global reach, distributing its products to roughly 38 countries across regions including Southeast Asia, other parts of Asia, both English and French-speaking African nations, the Middle East and North Africa, and the United States.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―